Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Cancer Immunol Res. 2014 Oct 29;3(2):206–216. doi: 10.1158/2326-6066.CIR-14-0163

Figure 2.

Figure 2

Toxicity and in vivo persistence of ROR1 CAR-T cells. A, body weight and serum chemistry before and at the indicated days after the T-cell infusion. The grey shaded area demarks the normal range for each parameter in rhesus macaques. B, plasma cytokine levels measured prior to and post-infusion. C, frequency of transferred T cells (%) within the CD3+CD4+ and CD3+CD8+ subsets in blood after infusion of ROR1 CAR and control EGFRt+ T cells. Stainings are with mAbs specific for CD3, CD4, CD8, and CD19 or EGFRt. D, absolute numbers of ROR1 CAR+ and EGFRt+T cells in the blood measured by flow cytometry and calculated based on the results of a CBC on the indicated days in an accredited clinical laboratory. E, real-time qPCR for the presence of transgene vector-specific DNA sequences in samples of PBMC obtained before and after T-cell transfer. The arrow indicates the T-cell infusion (D, E).